Novartis Annual Results

Annual results

Annual Results 2018 - Jan 30, 2019

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

Condensed financial report (PDF 0.6 MB)

Webcast and presentations

Media

Watch the webcast

Download the presentation (PDF 3.2 MB)

Investors

Watch the webcast

Read the presentation transcript

Download the presentation (PDF 3.4 MB)

2018 Annual Reporting Suite

Novartis Annual Review 2018

The Annual Review, our new corporate report, explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2018.

To request a hard copy of the Annual Report, fill out the order form.

Download the Annual Report 2018 (PDF 3.8 MB)

Visit the 2018 Annual Reporting Suite section

 

Form 20-F 

Novartis 20-F 2018

Form 20-F documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).

English (PDF 3.7 MB)

XBRL package

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.7 MB)

2018

Annual Results 2018 - Jan 30, 2019

 

Key figures1 FY 2018
(USD m)		 FY 2017
(USD m)		 % change
(USD/cc)
Net sales 51,900 49,109 6 (cc: 5)
Operating income 8,169 8,629 -5 (cc: -5)
Net income 12,614 7,703 64 (cc: 64)
EPS (USD) 5.44 3.28 66 (cc: 66)
Free cash flow 11,717 10,428 12

Core		      
Operating income 13,823 12,850 8 (cc: 8)
Net income 11,938 11,391 5 (cc: 5)
EPS (USD) 5.15 4.86 6 (cc: 6)

 

  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

 

Condensed financial report (PDF 0.6 MB)

Watch the webcast

Read the presentation transcript

Download the presentation (PDF 3.4 MB)

2017

Annual Results 2017 - Jan 24, 2018

 

Key figures1 FY 2017
(USD m)		 FY 2016
(USD m)		 % change
(USD/cc)
Net sales 49,109 48,518 1 (cc: 2)
Operating income 8,629 8,268 4 (cc: 7)
Net income 7,703 6,698 15 (cc: 12)
EPS (USD) 3.28 2.82 16 (cc: 14)
Free cash flow 10,428 9,455 10

Core		      
Operating income 12,850 12,987 -1 (cc: 0)
Net income 11,391 11,314 1 (cc: 2)
EPS (USD) 4.86 4.75 2 (cc: 3)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.3 MB)

Français (PDF 0.5 MB)

 

Condensed financial report (PDF 0.5 MB)

Download the presentation (PDF 2.8 MB)

Download the podcast (MP3 40 MB)

2016

Annual Results 2016 - Jan 25, 2017

 

Continuing operations2
Key figures1 FY 2016
(USD m)		 FY 2015
(USD m)		 % change
(USD/cc)
Net sales 48,518 49,414 -2 (cc: 0)
Operating income 8,268 8,977 -8 (cc: -3)
Net income 6,698 7,028 -5 (cc: 1)
EPS (USD) 2.82 2.92 -3 (cc: 2)
Free cash flow 9,455 9,259 2

Core		      
Operating income 12,987 13,790 -6 (cc: -2)
Net income 11,314 12,041 -6 (cc: -3)
EPS (USD) 4.75 5.01 -5 (cc: -2)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
2. Refers to continuing operations, defined on page 41 of the Condensed Financial Report.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.4 MB)

Français (PDF 0.4 MB)

 

Condensed financial report (PDF 0.5 MB)

Download the presentations:
Q4 and Full Year 2016 Results (PDF 2.7 MB)
Development Update (PDF 2.5 MB)
Research Update (PDF 2.4 MB)

Download the podcast (MP3 100 MB)

2015

Annual Results 2015 - Jan 27, 2016

 

Continuing operations2
Key figures1 FY 2015
(USD m)		 FY 2014
(USD m)		 % change
(USD/cc)
Net sales 49,414 52,180 -5 (cc: 5)
Operating income 8,977 11,089 -19 (cc: -2)
Net income 7,028 10,727 -34 (cc: -18)
EPS (USD) 2.92 4.39 -33 (cc: -17)
Free cash flow 9,259 10,934 -15

Core		      
Operating income 13,790 14,473 -5 (cc: 10)
Net income 12,041 12,653 -5 (cc: 9)
EPS (USD) 5.01 5.19 -3 (cc: 10)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 53 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

2. Refers to continuing operations, defined on page 43 of the Condensed Financial Report.

 

Media release

English (PDF 0.5 MB)

Deutsch (PDF 0.5 MB)

Français (PDF 0.8 MB)

 

Condensed financial report (PDF 0.6 MB)

 

 

2014

Annual Results 2014 - Jan 27, 2015

 

    excl. Diagnostics[1] Reported
  FY 2014[2]
(USD m)		 FY 2013
(USD m)		 % change
(USD/cc[1])		 FY 2013
(USD m)
Net sales 57,996 57,355 1 (cc: 3) 57,920
Operating income 10,736 10,671 1 (cc: 7) 10,910
Net income 10,280 9,144 12 (cc: 19) 9,292
EPS (USD) 4.21 3.70 14 (cc: 20) 3.76
Free cash flow 10,762 9,592 12 9,945

Core1		        
Operating income 14,616 14,191 3 (cc: 8)  
Net income 12,755 12,351 3 (cc: 8)  
EPS (USD) 5.23 5.01 4 (cc: 10)  

 

 

1. Constant currencies (cc), core results, free cash flow and 2013 data excluding the blood transfusion diagnostics unit are non-IFRS measures. An explanation of non-IFRS measures can be found on page 54 of the Condensed Financial Report (CFR).
2. 2014 results exclude depreciation and amortization related to discontinuing operations from the portfolio transformation announcement date. See page 22 of the CFR.

 

Media release

English (PDF 0.5 MB)

Deutsch (PDF 0.5 MB)

Français (PDF 0.8 MB)

Condensed financial report (PDF 0.6 MB)

Disclaimer: 

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Related Links

Presentations and Events

View recent presentations and learn more about upcoming events

Visit our Event Calendar
 

Contact Investor Relations

Investors International:
Call +41 61 324 79 44

Investors North America:
Call +1 212 830 24 48

Novartis Share Registry:
For information relating to the registration of your shares, including name or address changes, please contact us by e‑mail or telephone:
Call +41 61 324 72 04